Nuveen’s Ascendis Pharma A/S ASND Stock Holding History

Nuveen’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$24.1M	Buy	90,318 +84,267	+1,393%	+$19.7M	0.01%	1146
2026 Q1	$1.38M	Sell	6,051 -3,047	-33%	-$683K	﹤0.01%	2419
2025 Q4	$1.94M	Sell	9,098 -105	-1%	-$21.7K	﹤0.01%	2309
2025 Q3	$1.83M	Sell	9,203 -358	-4%	-$66.8K	﹤0.01%	2338
2025 Q2	$1.65M	Buy	+9,561	New	+$1.56M	﹤0.01%	2389
2025 Q1	–	Sell	-14,430	Closed	-$1.99M	–	3281
2024 Q4	$1.99M	Sell	14,430 -170	-1%	-$22.4K	﹤0.01%	2389
2024 Q3	$2.18M	Buy	+14,600	New	+$1.97M	﹤0.01%	2374
2020 Q4	–	Sell	-11,940	Closed	-$1.84M	–	3307
2020 Q3	$1.84M	Sell	11,940 -165	-1%	-$23.7K	﹤0.01%	2422
2020 Q2	$1.79M	Sell	12,105 -5,523	-31%	-$758K	﹤0.01%	2388
2020 Q1	$1.99M	Buy	17,628 +1,092	+7%	+$142K	﹤0.01%	2192
2019 Q4	$2.3M	Buy	16,536 +3,516	+27%	+$391K	﹤0.01%	2369
2019 Q3	$1.25M	Buy	13,020 +1,005	+8%	+$112K	﹤0.01%	2600
2019 Q2	$1.38M	Buy	12,015 +8,568	+249%	+$1.03M	﹤0.01%	2608
2019 Q1	$406K	Buy	+3,447	New	+$302K	﹤0.01%	869

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Nuveen's ASND Position: Q2 2026 in Review

Nuveen increased its Ascendis Pharma A/S (ASND) stake by 1,393% in Q2 2026, buying an estimated $19.7M and bringing the position to 90,318 shares worth $24.1M. The position accounts for 0.01% of the portfolio, ranked #1146.

Nuveen first reported a position in ASND in Q1 2019 and has held it in 14 quarters since. 312 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

Nuveen held 90,318 shares of Ascendis Pharma A/S worth $24.1M as of Q2 2026.
Nuveen bought 84,267 Ascendis Pharma A/S shares in Q2 2026, an estimated $19.7M.
Ascendis Pharma A/S made up 0.01% of Nuveen's portfolio in Q2 2026, its #1146 holding.
Nuveen first reported a position in Ascendis Pharma A/S in Q1 2019 and has held it in 14 quarters since.
312 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.